BrighTNess Follow-Up Data Shed Light on TNBC Therapy BrighTNess Follow-Up Data Shed Light on TNBC Therapy

Patients with triple negative breast cancer had improved event-free survival when carboplatin (but not the PARP inhibitor veliparib) was added to standard neoadjuvant chemotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news